US FDA Approves Bayer’s Darolutamide to Treat Metastatic HSPC
The US health agency approved Darolutamide, developed by Bayer, to treat patients with metastatic hormone-sensitive prostate cancer (HSPC). Darolutamide can be given alongside docetaxel plus androgen deprivation therapy (ADT). The efficacy of Darolutamide in the patients was demonstrated in the phase 2 trial. in particularly, use of Darolutamide despite placebo in combination with docetaxel plus […]
Continue Reading